← Analyst Upside
AU · rank #2 · 2026-07-22
DIA
GPW · PLN · $1.56B (USD)
SignalStrong Buy10.0strength 10.0 / 10
verdict · PROCEED
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.472 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | -$0.38 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $204.28 | +16.3% |
| Momentum acceleration 3-month minus 12-month momentum. | +20.23% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.33 |
| Gross margin TTM | +79.3% |
| 52w high | $214.46 |
| Market cap (USD) | $1.56B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Diagnostyka S.A. operates Poland's largest medical diagnostic laboratory network, offering over 4,000 tests via a nationwide hub-and-spoke model.
Rationale
Strong Q1 2026 financial performance, with net profit rising to PLN 82.6m and ROE exceeding 40%, validates the high 4.33 analyst rating and supports the 16.3% target price upside.
Material risks
- 1Long-term erosion of the centralized laboratory business model from the technological displacement and commoditization driven by point-of-care and home diagnostic tools.
- 2Loss of testing volumes if key institutional clients, such as medical facilities and universities, choose to insource their diagnostic capabilities.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.
OpenAI
Proceed
Claude
Caution
Gemini
Proceed